University of Alberta Research Team Publishes Preclinical Data in Cell Biomaterials on D-GK17, a Human-Derived Antimicrobial Peptide That Targets Bacterial and Fungal Biofilms (the Sticky Extracellular Matrix That Often Renders Traditional Antibiotic Treatments Impenetrable), Demonstrating Stability, Non-Toxicity to Human Cells, and Broad-Spectrum Activity Against Multidrug-Resistant Pathogens; The Team Is Filing a Patent Through the University of Alberta and Developing Gel and Bandage Delivery Formulations for Skin Infections and Cancer-Treatment-Related Mouth Ulcers, Extending the Rapidly-Growing Antimicrobial Peptide Therapeutic Category That the FDA PCAC February 2027 Docket Also Advances via the LL-37 (Cathelicidin) Peptide
A University of Alberta research team published preclinical data in Cell Biomaterials on D-GK17, a human-derived antimicrobial peptide that targets bacterial and fungal biofilms. Biofilms are the sticky extracellular matrix bacterial and fungal communities create that render traditional antibiotic treatments substantially less effective; biofilm-associated infections drive a major portion of antimicrobial resistance and hospital-acquired infection burden. D-GK17 demonstrated stability, non-toxicity to human cells, and broad-spectrum activity against multidrug-resistant pathogens in the preclinical work. The team is filing a patent through the University of Alberta and developing gel and bandage delivery formulations for skin infections and cancer-treatment-related mouth ulcers (chemotherapy and radiation-induced oral mucositis is a substantial unmet-need indication in oncology). D-GK17 extends the rapidly-growing antimicrobial peptide therapeutic category, which the FDA PCAC February 2027 docket also advances via the cathelicidin (LL-37) peptide review. The AMP category is under active development across marine-derived (shrimp SALF-based), computational (MAC-AMP AI design system), and human-derived platforms, with cross-cutting applications spanning antimicrobial resistance, cancer therapy, and antiviral therapy.